Phillip Frost (born c. 1936) is an American entrepreneur. Early life and education Frost was born into an observant Jewish family in the United States. He has two elder brothers, who are 15 and 16 years older than him respectively. Both brothers fought in World War II, one in the Air Force and one in the Army. At 13, he got his first job, working in a local hardware shop after school. Frost earned a B.A. in French literature from the University of Pennsylvania, in 1957. He received an M.D. degree from the Albert Einstein College of Medicine, in 1961 and attended the University of Paris, from 1955 to 1956. Career He served as a lieutenant commander, U.S. Public Health Service at the National Cancer Institute, from 1963 to 1965. Frost was a professor of dermatology at the University of Miami School of Medicine, from 1966 to 1972. He was chairman of the department of dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida, from 1972 to 1990. Key Pharmaceuticals Michael Jaharis and Frost bought Key Pharmaceuticals, Inc. in 1972. Frost was chairman of the board of directors of Key Pharmaceuticals, from 1972, until its acquisition by Schering-Plough in 1986, for $835 million. Frost's share was $100 million. Frost's estimated net worth in 1986 was $150 million. Ivax Corporation Frost served as chairman of the board of directors and chief executive officer of Miami pharmaceutical manufacturer Ivax Corporation from 1987. He sold Ivax in January 2006, for $7.4 billion, to Israel-based Teva Pharmaceuticals. Teva Pharmaceutical Industries Frost became vice chairman of Teva Pharmaceutical Industries in January 2006, when Teva acquired Ivax Corporation. He was named the chairman of the board of Teva, in March 2010 and was reelected to the position in May 2012 before stepping down in 2015. Protalix BioTherapeutics Frost was one of the first and largest investors in Protalix BioTherapeutics, investing $24 million in the company that would later go on to develop a U.S. Food and Drug Administration-approved treatment for Gaucher disease. He resigned from the company's board of directors in 2007. A 2010 U.S. Securities and Exchange Commission filing indicated that Frost donated around $8 million in Protalix shares to a charitable organization. Current business Frost became the CEO and chairman of OPKO Health, Inc. upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc., on March